μ-opioid receptor
View/Edit Human | View/Edit Mouse |
The μ-opioid receptors (MOR) are a class of
Structure
The structure of the inactive μ-opioid receptor has been determined with the antagonists β-FNA[6] and alvimopan.[7] Many structures of the active state are also available, with agonists including DAMGO,[8] β-endorphin,[9] fentanyl and morphine.[10] The structure with the agonist BU72 has the highest resolution,[11] but contains unexplained features that may be experimental artifacts.[12][13] This large body of evidence has enabled structure-based design of a new class of opioids with functional selectivity.[14]
Splice variants
Three variants of the μ-opioid receptor are well characterized, though reverse transcription polymerase chain reaction has identified up to 10 total splice variants in humans.[15][16][17]
μ1 | More is known about the μ1 opioid receptor than the other variants. |
μ2 | TRIMU 5 is a selective agonist of the μ2 receptor.[18] |
μ3 | The μ3 variant was first described in 2003.[19] It is responsive to opiate alkaloids but not opioid peptides.[20] |
Location
They can exist either presynaptically or postsynaptically depending upon cell types.
The μ-opioid receptors exist mostly
Some MORs are also found in the intestinal tract. Activation of these receptors inhibits peristaltic action which causes constipation, a major side effect of μ agonists.[21]
Activation
MOR can mediate acute changes in neuronal excitability via suppression of presynaptic release of
Activation of the μ-opioid receptor by an agonist such as
The canonical MOR1 isoform is responsible for morphine-induced analgesia, whereas the alternatively spliced MOR1D isoform (through heterodimerization with the gastrin-releasing peptide receptor) is required for morphine-induced itching.[23]
Deactivation
As with other
Long-term or high-dose use of opioids may also lead to additional mechanisms of tolerance becoming involved. This includes downregulation of MOR gene expression, so the number of receptors presented on the cell surface is actually reduced, as opposed to the more short-term desensitisation induced by β-arrestins or RGS proteins.[30][31][32] Another long-term adaptation to opioid use can be upregulation of glutamate and other pathways in the brain which can exert an opioid-opposing effect, so reduce the effects of opioid drugs by altering downstream pathways, regardless of MOR activation.[33][34]
Tolerance and overdoses
Fatal opioid overdose typically occurs due to bradypnea, hypoxemia, and decreased cardiac output (hypotension occurs due to vasodilation, and bradycardia further contributes to decreased cardiac output).[35][36][37] A potentiation effect occurs when opioids are combined with ethanol, benzodiazepines, barbiturates, or other central depressants which can result in rapid loss of consciousness and an increased risk of fatal overdose.[35][36]
Substantial tolerance to respiratory depression develops quickly, and tolerant individuals can withstand larger doses.[38] However, tolerance to respiratory depression is quickly lost during withdrawal and may be completely reversed within a week. Many overdoses occur in people who return to their previous dose after having lost their tolerance following cessation of opioids. This puts addicts who receive medical treatment for opioid addiction at great risk of overdose when they are released, as they may be particularly vulnerable to relapse.
Less commonly, massive overdoses have been known to cause
Opioid overdoses can be rapidly reversed through the use of opioid antagonists, naloxone being the most widely used example.[35] Opioid antagonists work by binding competitively to µ-opioid receptors and displacing opioid agonists. Additional doses of naloxone may be necessary and supportive care should be given to prevent hypoxic brain injury by monitoring vital signs.
See also
- δ-opioid receptor
- κ-opioid receptor
References
- ^ a b c GRCh38: Ensembl release 89: ENSG00000112038 – Ensembl, May 2017
- ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000000766 – Ensembl, May 2017
- ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
- ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
- PMID 10683246.
- PMID 22437502.
- PMID 36396979.
- PMID 29899455.
- S2CID 255750597.
- S2CID 253426623.
- PMID 26245379.
- S2CID 237649760.
- PMID 37817141.
- PMID 36450356.
- PMID 17094965.
- S2CID 22410194.
- PMID 28319053.
- S2CID 54354971.
- PMID 12734358.
- PMID 15173675.
- PMID 22493554.
- PMID 15659552.
- PMID 22000021.*Lay summary in: Dryden, J (October 13, 2011). "Researchers block morphine's itchy side effect". Washington University in St. Louis.
- S2CID 29491629.
- PMID 16115983.
- PMID 16750901.
- PMID 17723928.
- S2CID 23797166.
- PMID 17880927.
- PMID 18640146.
- S2CID 6310244.
- PMID 19482692.
- S2CID 9022097.
- PMID 19482614.
- ^ a b c Blok (2017). "Opioid toxicity" (PDF). Clinical Key. Elsevier.
- ^ PMID 23204873.
- PMID 22577457.
- PMID 32865832.
- S2CID 231613932.
- S2CID 24530179.
External links
- "Opioid Receptors: μ". IUPHAR Database of Receptors and Ion Channels. International Union of Basic and Clinical Pharmacology.
- mu+Opioid+Receptor at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
- Human OPRM1 genome location and OPRM1 gene details page in the UCSC Genome Browser.